Zonegran Postmarketing Skin/Renal AEs To Be Considered Unlabeled Events
Executive Summary
Elan should consider any postmarketing reports of allergic, skin, blood disorder and renal reactions with its new antiepileptic Zonegran to be unlabeled events, FDA told the company.
You may also be interested in...
Zonegran Label Revision Recommends Monitoring For Decreased Sweating
Patients on Elan's anticonvulsant Zonegran should be closely monitored for decreased sweating and increased body temperature, the company said in a "Dear Doctor" letter
Zonegran Label Revision Recommends Monitoring For Decreased Sweating
Patients on Elan's anticonvulsant Zonegran should be closely monitored for decreased sweating and increased body temperature, the company said in a "Dear Doctor" letter
Novartis Trileptal Has Fewer Hemopoietic, Dermatologic AEs Than Tegretol
Novartis' Trileptal labeling indicates that the anticonvulsant may be associated with fewer serious hemopoietic and dermatologic adverse events than the company's older antiseizure drug Tegretol.